ArticleThe Lancet. Haematology2022

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.

Reuben Benjamin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.